Prediction of Propofol Effect Compartment Concentrations (Propo2022)
The goal of this observational study is to learn about the prediction of the effect of Propofol by means of EEGs. The main questions it aims to answer are:
- Develop models that can reliably predict the effect of Propofol
- Select the most well suited model for clinical practice
- Compare this model to already existing models (e.g. Schnider-model)
Participants will asked to allow us to collect and use the EEG data recorded during the operations.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Robert Fritze, MD
- Phone Number: ++43/2732/9004-14055
- Email: Robert.Fritze@krems.lknoe.at
Study Locations
-
-
Niederösterreich
-
Krems, Niederösterreich, Austria, 3500
- Recruiting
- Klinische Abteilung für Anästhesie und Intensivmedizin
-
Contact:
- Robert Fritze, MD
- Phone Number: ++43/2732/9004-14055
- Email: Robert.Fritze@krems.lknoe.at
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age of 18 or older at the time of the signature of the informed consent
- Signed informed consents
- Planned TIVA with Propofol
Exclusion Criteria:
- Use of extracorporal circulation (e.g., HLM, ECMO)
- Admission to an ICU/IMCU before the operation or planned admission to an ICU/IMCU after the operation
- Administration of Propofol seven days prior to the planned operation
- Missing informed consent
- All contraindications against TIVA (e.g., allergy against Propofol or soy)
- All operations where BIS monitoring cannot be used (e.g., skin lesions on the front)
- Patients for which the administration of Propofol could be potentially harmfull (e.g., severe heart failure with the risk of drop of blood pressure)
- Neurosurgical operations
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bilateral BIS values (derived from EEG)
Time Frame: During procedure (From the beginning of general anaesthesia (induction of anaesthesia) until the patient has woken up (end of anaesthesia)).
|
Comparison of Predicted and Measured EEG values (recorded every five seconds)
|
During procedure (From the beginning of general anaesthesia (induction of anaesthesia) until the patient has woken up (end of anaesthesia)).
|
|
Propofol cumulative dose
Time Frame: During procedure (From the beginning of general anaesthesia (induction of anaesthesia) until the patient has woken up (end of anaesthesia)).
|
Cumulative dose of Propofol (recorded every second)
|
During procedure (From the beginning of general anaesthesia (induction of anaesthesia) until the patient has woken up (end of anaesthesia)).
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SF44
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.